Nanotechnology and Drug Delivery: An Update in Oncology
The field of nanotechnology has exploded in recent years with diverse arrays of applications. Cancer therapeutics have recently seen benefit from nanotechnology with the approval of some early nanoscale drug delivery systems. A diversity of novel delivery systems are currently under investigation an...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2011-04-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4923/3/2/171/ |
id |
doaj-d463f0bbb6e04505ad32e2bf2726cc0b |
---|---|
record_format |
Article |
spelling |
doaj-d463f0bbb6e04505ad32e2bf2726cc0b2020-11-24T21:58:28ZengMDPI AGPharmaceutics1999-49232011-04-013217118510.3390/pharmaceutics3020171Nanotechnology and Drug Delivery: An Update in OncologyTait JonesNabil SabaThe field of nanotechnology has exploded in recent years with diverse arrays of applications. Cancer therapeutics have recently seen benefit from nanotechnology with the approval of some early nanoscale drug delivery systems. A diversity of novel delivery systems are currently under investigation and an array of newly developed, customized particles have reached clinical application. Drug delivery systems have traditionally relied on passive targeting via increased vascular permeability of malignant tissue, known as the enhanced permeability and retention effect (EPR). More recently, there has been an increased use of active targeting by incorporating cell specific ligands such as monoclonal antibodies, lectins, and growth factor receptors. This customizable approach has raised the possibility of drug delivery systems capable of multiple, simultaneous functions, including applications in diagnostics, imaging, and therapy which is paving the way to improved early detection methods, more effective therapy, and better survivorship for cancer patients. http://www.mdpi.com/1999-4923/3/2/171/drug delivery systemsnanotechnologycancerpassive targetingactive targeting |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tait Jones Nabil Saba |
spellingShingle |
Tait Jones Nabil Saba Nanotechnology and Drug Delivery: An Update in Oncology Pharmaceutics drug delivery systems nanotechnology cancer passive targeting active targeting |
author_facet |
Tait Jones Nabil Saba |
author_sort |
Tait Jones |
title |
Nanotechnology and Drug Delivery: An Update in Oncology |
title_short |
Nanotechnology and Drug Delivery: An Update in Oncology |
title_full |
Nanotechnology and Drug Delivery: An Update in Oncology |
title_fullStr |
Nanotechnology and Drug Delivery: An Update in Oncology |
title_full_unstemmed |
Nanotechnology and Drug Delivery: An Update in Oncology |
title_sort |
nanotechnology and drug delivery: an update in oncology |
publisher |
MDPI AG |
series |
Pharmaceutics |
issn |
1999-4923 |
publishDate |
2011-04-01 |
description |
The field of nanotechnology has exploded in recent years with diverse arrays of applications. Cancer therapeutics have recently seen benefit from nanotechnology with the approval of some early nanoscale drug delivery systems. A diversity of novel delivery systems are currently under investigation and an array of newly developed, customized particles have reached clinical application. Drug delivery systems have traditionally relied on passive targeting via increased vascular permeability of malignant tissue, known as the enhanced permeability and retention effect (EPR). More recently, there has been an increased use of active targeting by incorporating cell specific ligands such as monoclonal antibodies, lectins, and growth factor receptors. This customizable approach has raised the possibility of drug delivery systems capable of multiple, simultaneous functions, including applications in diagnostics, imaging, and therapy which is paving the way to improved early detection methods, more effective therapy, and better survivorship for cancer patients. |
topic |
drug delivery systems nanotechnology cancer passive targeting active targeting |
url |
http://www.mdpi.com/1999-4923/3/2/171/ |
work_keys_str_mv |
AT taitjones nanotechnologyanddrugdeliveryanupdateinoncology AT nabilsaba nanotechnologyanddrugdeliveryanupdateinoncology |
_version_ |
1725851814359728128 |